BDSX
BIODESIX INC
Overview
BIODESIX INC is a Healthcare company operating in Diagnostics & Research with a $179.7M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 5, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-0414 Q&A exchanges
- Q4 FY2025Earnings2026-02-2614 Q&A exchanges
- Q3 FY2025Earnings2025-11-038 Q&A exchanges
- Q2 FY2025Earnings2025-08-0915 Q&A exchanges
- Q1 FY2025Earnings2025-05-1320 Q&A exchanges
- Q4 FY2024Earnings2025-03-0319 Q&A exchanges
- Q3 FY2024Earnings2024-11-0123 Q&A exchanges
- Q2 FY2024Earnings2024-08-078 Q&A exchanges
- Q1 FY2024Earnings2024-05-1012 Q&A exchanges
- Q4 FY2023Earnings2024-03-0114 Q&A exchanges
- Q3 FY2023Earnings2023-11-1121 Q&A exchanges
- Q2 FY2023Earnings2023-08-0714 Q&A exchanges
- Q1 FY2023Earnings2023-05-1410 Q&A exchanges
- Q4 FY2022Earnings2023-03-0610 Q&A exchanges
- Q3 FY2022Earnings2022-11-0619 Q&A exchanges
- Q2 FY2022Earnings2022-08-0619 Q&A exchanges
- Q1 FY2022Earnings2022-05-1116 Q&A exchanges
- Q4 FY2021Earnings2022-03-1415 Q&A exchanges
- Q3 FY2021Earnings2021-11-1516 Q&A exchanges
- Q2 FY2021Earnings2021-08-1011 Q&A exchanges
- Q1 FY2021Earnings2021-05-1112 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-05EPS— vs $-0.88—Rev— vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-05 | — | $-0.88 | — | — | — | — | EODHD |
Source: EODHD. BDSX reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks BDSX's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $1.56 | $1.78 | -12.6% | +3.1% | +1.5% |
| Q4 FY2026 | $1.28 | $1.70 | -24.8% | +4.5% | +4.8% |
| Q3 FY2026 | $1.52 | $1.84 | -17.6% | +8.0% | +9.4% |
| Q2 FY2026 | $1.32 | $1.69 | -21.9% | +3.0% | +0.2% |
| Q1 FY2025 | $1.47 | $1.79 | -18.0% | +6.5% | +5.7% |
| Q4 FY2025 | $1.33 | $1.75 | -24.1% | +7.0% | +5.7% |
| Q3 FY2025 | $1.43 | $1.98 | -27.9% | +6.8% | +5.6% |
| Q2 FY2025 | $1.46 | $1.96 | -25.5% | +5.1% | +2.6% |
| Q1 FY2024 | $1.55 | $1.92 | -19.2% | +7.4% | +5.8% |
| Q4 FY2024 | $1.57 | $2.02 | -22.3% | -0.6% | -3.2% |
Guidance change history
Sample- Q1 FY2026Lowered2026-04-15
- Q4 FY2026Lowered2026-13-15
- Q3 FY2026Lowered2026-10-15
- Q2 FY2026Lowered2026-07-15
- Q1 FY2025Lowered2025-04-15
- Q4 FY2025Lowered2025-13-15
- Q3 FY2025Lowered2025-10-15
- Q2 FY2025Lowered2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Scott HuttonCEO10 mo21 callsCurrentSample
CEO since 2025 • 3/4 beats (75%) • last guidance cut Q1 FY2026
- Robin Harper CowieCFO10 mo18 callsCurrentSample
CFO since 2025 • 3/4 beats (75%) • last guidance raise Q3 FY2026
- Gary Anthony PestanoChief Development Officer7 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 3/4 beats (75%) • guidance suspended Q3 FY2026
- Kieran O'KaneChief Commercial Officer7 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 2/4 beats (50%) • last guidance raise Q2 FY2026
- Chris VazquezChief Accounting Officer7 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 3/4 beats (75%) • last guidance raise Q2 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for BDSX.
$ curl https://api.spokenalpha.com/v1/companies/BDSXFAQ
Frequently asked about BDSX
Where can I find BIODESIX INC's (BDSX) earnings call transcripts?
Spoken Alpha indexes BDSX's earnings call transcripts at https://spokenalpha.com/companies/BDSX. Each call links to attributed speakers and parsed analyst Q&A. BIODESIX INC's own investor relations page is at https://investors.biodesix.com/.
When was BIODESIX INC's most recent earnings call?
BIODESIX INC (BDSX) held its most recent earnings call on 2026-05-04, covering fiscal Q1 2026.
What sector is BDSX in?
BIODESIX INC (BDSX) operates in the Healthcare sector (Diagnostics & Research industry).